|
Jun 4
|
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
|
|
Jun 4
|
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
|
|
Jun 2
|
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial
|
|
Jun 1
|
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
|
|
May 31
|
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial
|
|
May 8
|
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
|
|
May 7
|
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
|
|
May 2
|
TAK or DSNKY: Which Is the Better Value Stock Right Now?
|
|
Jan 31
|
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
|
|
Jan 31
|
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
|
|
Jan 29
|
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
|
|
Jan 28
|
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
|
|
Jan 27
|
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
|
|
Oct 14
|
ENHERTU gains conditional approval in China to treat NSCLC
|
|
Jun 24
|
Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan
|
|
Feb 19
|
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
|
|
Feb 16
|
Daiichi invests 1 bln eur near Munich to make precision cancer drugs
|
|
Jan 8
|
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
|
|
Jan 4
|
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
|
|
Jan 3
|
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
|